San Francisco, CA—Percutaneous closure of the patent ductus arteriosus (PDA) in children using a novel device is safe and effective, according to a prospective study presented in a featured clinical ...

New innovative capability brings lifesaving cardiac care directly to the NICU, reducing risks associated with transporting fragile premature infants. MIAMI , Sept. 22, 2025 /PRNewswire/ -- Nicklaus ...

Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo occluder ...

Please provide your email address to receive an email when new articles are posted on . Compared with surgical ligation, transcatheter closure of the patent ductus arteriosus in infants and neonates ...

In 2019, the U.S. Food and Drug Administration approved the first PDA occlusion device for infants as small as 700 grams, leading to rapid adoption of tcPDA in premature infants. Catheter-based ...

The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

MEMPHIS, Tenn. - Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

The pea-sized device is a self-expanding wire mesh that is inserted through an incision in the leg and guided through vessels to the heart, where it is placed to seal the opening. The Food and Drug ...

In cases where a PDA does not respond to medication or close on its own, closure may be needed to stabilize the infant's condition. The minimally invasive procedure involves placing a small catheter ...